Making Better Drugs for Children with Cancer

Making Better Drugs for Children with Cancer PDF download.

Making Better Drugs for Children with Cancer

AGENTS IN USE AND IN TESTING FOR CHILDREN WITH CANCER, THE EXISTING CAPACITY FOR DEVELOPING NEW AGENTS SPECIFICALLY FOR CHILDHOOD CANCERS

• Developmental Therapeutics Program,
• Drug Discovery Resources,
• Drug Discovery Screening Services,
• Drug Discovery Databases and Analytical Tools,
• Access to Discovery Resources: The RAND Program,
• Drug Development Resources,
• Access to Drug Development Resources: RAID,
• Access to Drug Development Resources: NCI Drug
• Development Group, Clinical Trials: The Children’s Oncology Group,  PUTTING THE PIECES TOGETHER, Drug Discovery, Drug Testing, Preclinical Testing, Clinical Trials,  What Is Missing?,

DELAYS IN TESTING APPROVED AGENTS IN CHILDREN,

• Starting Pediatric Trials Earlier in the Drug Development Process, Completing Pediatric Clinical Trials More Quickly,

THE NEED TO PRIORITIZE AGENTS FOR TESTING IN CHILDREN WITH CANCER, TESTING AND LABELING OF DRUGS FOR PEDIATRIC USE

The Pediatric Rule, The Short-Lived 1994 Pediatric Rule, The 1998 Pediatric Final Rule and the Pediatric  Research Equity Act of 2003, Pediatric  Subcommittee of the FDA Oncologic Drugs  Advisory Committee, Types of Childhood Cancer,  Leukemias, Central Nervous System Tumors and  Miscellaneous Intracranial and Intraspinal  Neoplasms, Neuroblastoma and Other Sympathetic  Nervous System Tumors, Lymphomas and Other  Reticuloendothelial Neoplasms,Soft-Tissue  Sarcomas, Malignant Bone Tumors, Renal Tumors, Retinoblastoma